Miami Clinical Research

1. AstraZeneca Pharmaceuticals LP $1,671,030 10 payments
2. Supernus Pharmaceuticals, Inc. $1,547,547 75 payments
3. Moderna TX, Inc. $1,099,962 21 payments
4. Regeneron Pharmaceuticals, Inc. $593,976 1,453 payments
5. Cue Health Inc. $391,591 2 payments
6. Merck Sharp & Dohme Corporation $305,630 5 payments
7. Pfizer Inc. $250,525 39 payments
8. Welch Allyn $145,879 9 payments
9. Amgen Inc. $69,650 5 payments
10. Ucb SA $16,500 1 payment

1. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $1,099,723 18 payments
2. A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma $1,074,211 5 payments
3. Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Spn-812 Er for the Treatment of Pediatric Patients With Attention Deficit/Hyperactivity Disorder (Adhd) $825,875 27 payments
4. Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) $593,976 1,453 payments
5. A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma $519,526 3 payments
6. Influenza, RSV $389,335 1 payment
7. A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression $248,165 1 payment
8. Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Spn-812 Er for the Treatment of Pediatric Patients With Attention Deficithyperactivity Disorder Adhd $246,752 7 payments
9. A Phase 1 Randomized and Phase 2 Study to Evaluate the Safety Tolerability Immunogenicity and Immunopersistence of A Clostridioides Difficile Vaccine Administered in A 2Dose Regimen With Novel Adjuvants in Healthy Adults $243,776 18 payments
10. A Phase IV, Open-Label, Flexible-Dose Safety Trial Evaluating Spn-812 Administered With Psychostimulants in Children and Adolescents (6 to 17 Years of Age) With Disorder (Adhd) Attention-Deficit/Hyperactivity $210,106 10 payments

1. Other $145,879 9 payments
2. Patient care $125,717 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.